Homologous recombination deficiency (HRD) in 543 ovarian cancer samples: A single center hands-on experience

被引：0
|
作者：
Kotsakis, A. [1 ]
Konstantoulakis, P. [2 ]
Christopoulou, G. [2 ]
Samara, S. [2 ]
Oikonomaki, A. [2 ]
Roumelioti, K. [2 ]
Pachitsa, F. [2 ]
Koinis, F. [3 ]
Georgoulias, V. [4 ]
机构：
[1] Univ Gen Hosp Larissa, Dept Med Oncol, Larisa, Greece
[2] Genotypos Sci Labs, Genom, Athens, Greece
[3] Univ Hosp Larissa, Dept Med Oncol, Larisa, Greece
[4] Metropolitan Gen Hosp, Dept Med Oncol 1, Iraklion, Greece
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.709
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
581P
引用
收藏
页码：S813 / S813
页数：1
相关论文
共 50 条
  • [31] The impact of homologous recombination deficiency on the prognosis of epithelial ovarian cancer
    Su, Haiqi
    Wang, Yinan
    Chao, Xiaopei
    Wu, Huanwen
    You, Yan
    Zhao, Shuru
    Wang, Feiyue
    Sun, Bao
    Zhang, Zhen
    Wu, Ming
    Zhao, Zicheng
    Li, Lei
    CLINICAL AND TRANSLATIONAL MEDICINE, 2025, 15 (01):
  • [32] Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
    Konstantinopoulos, Panagiotis A.
    Ceccaldi, Raphael
    Shapiro, Geoffrey I.
    D'Andrea, Alan D.
    CANCER DISCOVERY, 2015, 5 (11) : 1137 - 1154
  • [33] Genomic characteristics of homologous recombination deficiency in ovarian cancer.
    Ma, Xiaoxue
    Li, Mingwei
    Lou, Feng
    Cao, Shanbo
    Wang, Huina
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17575 - E17575
  • [34] The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors
    Hana Kim
    Soomin Ahn
    Hongsik Kim
    Jung Yong Hong
    Jeeyun Lee
    Se Hoon Park
    Joon Oh Park
    Young Suk Park
    Ho Yeong Lim
    Won Ki Kang
    Kyoung-Mee Kim
    Seung Tae Kim
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 2427 - 2435
  • [35] The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors
    Kim, Hana
    Ahn, Soomin
    Kim, Hongsik
    Hong, Jung Yong
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Won Ki
    Kim, Kyoung-Mee
    Kim, Seung Tae
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (09) : 2427 - 2435
  • [36] Streamline of the gene line: Implementation of reflex homologous recombination deficiency (HRD) tumor testing in newly diagnosed ovarian cancer patients
    Byrne, Maureen
    Mckenna, Danielle
    Schumacher, Ryan
    Shah, Payal
    Mastroyannis, Spyridon Alexandros
    Lodise, Amy
    Oliver, Sirithepphavanh
    Schwartz, Lauren
    Martin, Lainie
    Domchek, Susan
    Haggerty, Ashley
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S287 - S288
  • [37] Pathogenic Germline Mutations of Homologous Recombination Deficiency (HRD) Genes in Chinese Lung Cancer Patients
    Wang, M.
    Li, S.
    Xue, X.
    Wei, X.
    Ye, Z.
    Su, Y.
    Li, L.
    Xu, Z.
    Guo, T.
    Xie, J.
    Wang, W.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S534 - S534
  • [38] Clinical significance of homologous recombination deficiency (HRD) score testing in endometrial cancer patients.
    Hansen, Jean M.
    Ring, Karl Lassen
    Baggerly, Keith A.
    Wu, Sherry
    Timms, Kirsten
    Neff, Christopher
    Hughes, Elisha
    Previs, Rebecca A.
    Broaddus, Russell
    Coleman, Robert L.
    Lu, Karen H.
    Sood, Anil
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] Predictive value of homologous recombination deficiency (HRD) scores for abiraterone efficacy in metastatic prostate cancer
    Zhao, J.
    Zhu, Q.
    Shi, Y.
    Zeng, H.
    ANNALS OF ONCOLOGY, 2024, 35
  • [40] Causative Genes of Homologous Recombination Deficiency (HRD)-Related Breast Cancer and Specific Strategies at Present
    Nakamura, Seigo
    Kojima, Yasuyuki
    Takeuchi, Sayoko
    CURRENT ONCOLOGY, 2025, 32 (02)
12345